Immuneering Co. (NASDAQ:IMRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $12.60.
IMRX has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 target price on shares of Immuneering in a research note on Friday, September 13th. Chardan Capital dropped their price objective on shares of Immuneering from $16.00 to $12.00 and set a "buy" rating for the company in a research report on Wednesday, August 7th.
Check Out Our Latest Analysis on Immuneering
Immuneering Stock Down 6.5 %
IMRX stock traded down $0.14 during midday trading on Friday, reaching $2.01. 395,571 shares of the company's stock traded hands, compared to its average volume of 2,380,050. The company has a market cap of $59.60 million, a price-to-earnings ratio of -1.07 and a beta of -0.45. The company has a 50-day simple moving average of $1.93 and a two-hundred day simple moving average of $1.59. Immuneering has a 1-year low of $1.00 and a 1-year high of $8.89.
Immuneering (NASDAQ:IMRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. Equities research analysts forecast that Immuneering will post -1.89 EPS for the current year.
Institutional Trading of Immuneering
Institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. bought a new position in shares of Immuneering in the 3rd quarter worth $25,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Immuneering during the second quarter worth about $44,000. XTX Topco Ltd grew its position in shares of Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company's stock worth $44,000 after buying an additional 9,274 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Immuneering during the 2nd quarter worth about $67,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Immuneering in the 2nd quarter valued at about $447,000. Institutional investors and hedge funds own 67.65% of the company's stock.
About Immuneering
(
Get Free ReportImmuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Articles
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
